stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) EPS (diluted)
Replimune Group, Inc.'s EPS (diluted) for fiscal 2026 was −$3.38, compared with −$3.07 in fiscal 2025. Over the twelve months to 30 September 2026 it was −$2.79. Over the past ten years it has ranged from −$3.96 (fiscal 2018) to −$1.33 (fiscal 2019); the current reading is higher than 20% of that period. Replimune Group, Inc. ranks 373rd of 582 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | −$3.38 | — |
| FY2025 | −$3.07 | — |
| FY2024 | −$3.24 | — |
| FY2023 | −$2.99 | — |
| FY2022 | −$2.26 | — |
| FY2021 | −$1.75 | — |
| FY2020 | −$1.54 | — |
| FY2019 | −$1.33 | — |
| FY2018 | −$3.96 | — |
| FY2017 | −$1.55 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.54 | — |
| Jun 2026 | −$0.72 | — |
| Mar 2026 | −$0.76 | — |
| Dec 2025 | −$0.77 | — |
| 34 more quarters | Free account |
Against its own ten years
Low −$3.96
High −$1.33
Ten-year median
−$2.63
Current reading's percentile
20
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| ZYME Zymeworks Inc. compare | $0.52 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$0.29 |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$0.90 |
| VIR Vir Biotechnology, Inc. compare | −$1.26 |
| IMNM Immunome, Inc. compare | −$2.64 |
| REPL Replimune Group, Inc. | −$2.79 |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$5.17 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item